RegeneRx is a publicly traded, clinical stage, biopharmaceutical company engaged in the design, research and development of novel peptides targeted at diseases with unmet medical needs. RegeneRx s mission is to research and develop novel pharmaceuticals that protect and repair tissue and organ damage caused by disease, trauma or other pathology.
Quote | Regenerx Biopharms Inc (OTCMKTS:RGRX)
Last: | $0.0014 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $0.0014 |
High: | $0 |
Low: | $0 |
Volume: | 5 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Regenerx Biopharms Inc (OTCMKTS:RGRX)
RegeneRx Effects Reverse Stock Split and Terminates SEC Reporting Obligations PR Newswire ROCKVILLE, Md. , Aug. 15, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or the "Company") , a clinical-stage drug development compa...
2023-08-08 04:32:15 ET As of August 3, RegeneRx Biopharmaceuticals ( OTCQB:RGRX ) received consents from 51.7% stockholders in favor of the proposed reverse stock split, which is a prerequisite to allowing the company to suspend its public reporting obligations and become a non-re...
Message Board Posts | Regenerx Biopharms Inc (OTCMKTS:RGRX)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $RGRX News Article - First Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Cl | whytestocks | investorshangout | 04/13/2023 12:10:45 PM |
https://www.stockscores.com/chart.asp?TickerSymbol=%20rgrx&TimeRange=365&Interva | The Night Stalker | investorshub | 05/17/2022 4:25:36 AM |
scam bullshit is shell risk now | The Night Stalker | investorshub | 05/09/2022 12:49:21 AM |
https://www.stockscores.com/chart.asp?TickerSymbol=rgrx&TimeRange=1825&Interval= | The Night Stalker | investorshub | 05/09/2022 12:45:19 AM |
Dime time. | willlbone | investorshub | 03/02/2022 3:40:05 PM |
News, Short Squeeze, Breakout and More Instantly...
Regenerx Biopharms Inc Company Name:
RGRX Stock Symbol:
OTCMKTS Market:
RegeneRx Effects Reverse Stock Split and Terminates SEC Reporting Obligations PR Newswire ROCKVILLE, Md. , Aug. 15, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or the "Company") , a clinical-stage drug development compa...
RegeneRx Receives Stockholder Approval for Reverse Stock Split PR Newswire ROCKVILLE, Md. , Aug. 7, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or the "Company") , a clinical-stage drug development company focused o...
RegeneRx To Extend Consent Solicitation Vote PR Newswire ROCKVILLE, Md. , Aug. 1, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair, and...